Shares of Hims & Hers Health (NYSE: HIMS) plummeted over 12% in after-hours trading following a disappointing Q1 FY2026 earnings report, marking the company’s fourth consecutive miss on both earnings and revenue. Despite high expectations stemming from a partnership with Novo Nordisk to distribute its GLP-1 weight loss drugs, the company reported a loss of $0.40 per share and revenue of $608.1 million, falling short of analyst estimates and reflecting only 3.8% year-over-year growth.
The financial implications are significant, as the restructuring charges, including a $28 million write-down related to the GLP-1 strategy, have raised concerns about profitability. However, Hims & Hers is pivoting towards international expansion and has raised its full-year revenue guidance, signaling potential for future growth in a rapidly expanding telehealth market projected to reach over $455 billion by 2030.
For market professionals, the key takeaway is the mixed outlook: while short-term volatility is likely given the recent selloff and high short interest, the long-term growth prospects in the telehealth and weight loss sectors could provide opportunities for strategic investors willing to navigate the current turbulence.
Source: marketbeat.com